Article

Rheumatoid Arthritis (RA): More Than a Disease of the Joints

Kevin Mange, MD, MSCE, head of North America Medical Immunology at Sanofi, provides a comprehensive overview of the considerations in the treatment of rheumatoid arthritis, which carries comorbidities that affect multiple organ systems.

.

Related Videos
Jonathan Eisengart
1 expert is featured in this series.
5 experts are featured in this series.
Related Content
MASH is the inflammatory, progressed form of MASLD | image credit: Rasi - stock.adobe.com
January 20th 2025

A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins

Kyle Munz
Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver disease (MASLD).
Managed Care Cast
January 14th 2025

Frameworks for Advancing Health Equity: Accessing Ketamine-Assisted Therapy

Giuliana Grossi
Jessica Tracy, head of Growth and Partnerships at Enthea, shares how employers and unions can support mental health and address access barriers to evidence-based ketamine treatments.
Two abstracts presented at ASH 2024 provided insight into MDS response to hypomethylating agents (HMAs) | Image credit: Sviatlana - stock.adobe.com
January 19th 2025

Exploring Response to HMAs for MDS Across Various Patient Types

AJMC Contributor
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs).
AJMC Managed Care Cast
December 31st 2024

AJMC® Editors Reflect on 2024 and Look Forward to a Milestone

Christina Mattina
The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Center on Health Equity and Access
January 18th 2025

Health Equity & Access Weekly Roundup: January 18, 2024

Giuliana Grossi
The Center on Health Equity & Access provides news and expert insights on research, health policy, and the impact of social determinants on health.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo